Levodopa CAS 59-92-7
€180 – €570
Synonyms: (-)-Dopa, (S)-3,4-Dihydroxyphenylalanine, 3-Hydroxytyrosine, L-DOPA, Alphadopa, Bendopa, Brocadopa, Cidandopa, Deadopa, Dopaflex, Dopaidan, Dopal, Dopalina, Dopar, Doparkine, Doparl, Dopasol, Dopaston, Dopastral, Dopicar, Doprin, Eldopal, Eldopar, Laradopa, Maipedopa, Parda, Pardopa, Syndopa, Veldopa, Weldopa
250 g | € 180 |
500 g | € 260 |
1 kg | € 350 |
2 kg | € 570 |
Cat. No. | NST-10-208 |
CAS | 59-92-7 |
Purity | 98% (HPLC) |
Appearance | White powder |
Molecular formula | C9H11NO4 |
Molecular weight | 197,19 |
Storage | +2 … +8 °C |
Certificate of analysis available by request to [email protected]
Levodopa: Essential Precursor in Parkinson’s Disease Research
1. Molecular Identity
- Chemical Name: (S)-2-Amino-3-(3,4-dihydroxyphenyl)propanoic acid
- CAS Number: 59-92-7
- Source: Synthetic amino acid, also found naturally in certain plants
2. Biochemical Significance
Levodopa (L-DOPA) is the immediate precursor of dopamine, a crucial neurotransmitter in the central nervous system. Its ability to cross the blood-brain barrier and convert to dopamine makes it a cornerstone in neuropharmacological research, especially in studies related to Parkinson’s disease and motor function disorders.
3. Key Research Properties
- Dopamine Precursor: Increases central dopamine levels
- Model Compound: Widely used in Parkinson’s disease models
- Blood-Brain Barrier Penetration: Efficient CNS availability
- Neurotransmitter Modulation: Impacts dopaminergic signaling pathways
4. Potential Research Applications
- Optimization of Parkinson’s treatment strategies
- Neurodegenerative disease modeling
- Studies of dopaminergic neurotransmission
- Investigations in movement and motor control disorders
5. Current Research Focus
Ongoing studies are exploring Levodopa’s role in:
- Long-term efficacy and tolerance mechanisms
- Combination strategies to enhance CNS effects
- Formulation and CNS-targeted delivery development
- Applications in other neurological conditions
6. Formulation Challenges and Innovations
Researchers are actively developing:
- Extended-release and controlled-release systems
- Formulations minimizing peripheral conversion and side effects
- Targeted CNS delivery platforms
7. Regulatory Considerations
Levodopa (CAS 59-92-7) is used in pharmaceutical formulations approved for Parkinson’s disease. Its application in research should follow appropriate regulatory and ethical guidelines for laboratory and preclinical use.
8. Future Research Directions
Anticipated areas of exploration include:
- Neuroprotective potential in early-stage neurodegeneration
- Personalized dosing strategies based on patient profiles
- Innovative delivery methods for enhanced CNS selectivity
9. Collaborative Opportunities
We welcome inquiries from neuroscientists, pharmaceutical research teams, and academic institutions interested in Levodopa for their R&D needs. For technical specifications, samples, or partnership opportunities, contact us at [email protected].
Join us in supporting advanced neurological research with Levodopa – a key compound in the study of dopamine metabolism and CNS function.